Trial site

Aichi

Aichi, 466-8560, JapanNot linked to an institution yet

18running trials
7closed trials

The trials here

What the 25 trials at this site are about, from their registry records.

Conditions: Multiple myeloma6 trials
Asthma4 trials
HIV3 trials
Colorectal cancer2 trials
Endometrial cancer2 trials
Head and neck cancer2 trials
Bronchiectasis1 trial
Chronic kidney disease1 trial
Lung cancer1 trial
Lupus (SLE)1 trial
Pancreatic cancer1 trial
Systemic sclerosis (scleroderma)1 trial
and 1 more
Phase: Phase 318 trials
Phase 25 trials
Phase 11 trial
Phase 1/21 trial
Status: Active, not recruiting9 trials
Recruiting9 trials
Completed7 trials
Lead sponsor: GlaxoSmithKline22 trials
ViiV Healthcare3 trials

Running trials

Recruiting
A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed
NCT07650916· Phase 3· ViiV Healthcare· Source
Contact: Yoshiyuki Yokomaku (principal investigator)
Recruiting
A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)
NCT07286331· Phase 3· GlaxoSmithKline· Source
Contact: Hiroaki Kajiyama (principal investigator)
Recruiting
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
NCT07227311· Phase 2· GlaxoSmithKline· Source
Contact: Shinsuke Iida (principal investigator)
Recruiting
A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis
NCT07201051· Phase 2· GlaxoSmithKline· Source
Contact: Taku Nakagawa (principal investigator)
Recruiting
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
NCT06885034· Phase 1/2· GlaxoSmithKline· Source
Contact: Kei Muro (principal investigator)
Recruiting
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
NCT06679101· Phase 3· GlaxoSmithKline· Source
Contact: Shinsuke Iida (principal investigator)
Recruiting
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
NCT06716606· Phase 3· GlaxoSmithKline· Source
Contact: Hidekata Yasuoka (principal investigator)
Active, not recruiting
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
NCT06472076· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer
NCT06317311· Phase 2· GlaxoSmithKline· Source
Recruiting
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588· Phase 3· GlaxoSmithKline· Source
Contact: Nobuhiro Hanai (principal investigator)
Active, not recruiting
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy
NCT05979311· Phase 3· ViiV Healthcare· Source
Active, not recruiting
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
NCT06062420· Phase 2· GlaxoSmithKline· Source
Recruiting
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200· Phase 3· GlaxoSmithKline· Source
Contact: Toshiki Masuishi (principal investigator)
Active, not recruiting
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
NCT04915755· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
NCT04484623· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT04246047· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT04162210· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants
NCT02938520· Phase 3· ViiV Healthcare· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Colorectal cancer2 recruiting
Multiple myeloma2 recruiting
Bronchiectasis1 recruiting
Endometrial cancer1 recruiting
Head and neck cancer1 recruiting
HIV1 recruiting
Pancreatic cancer1 recruiting
Systemic sclerosis (scleroderma)1 recruiting

Closed trials

Completed
Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P)
NCT05682326· Phase 3· GlaxoSmithKline· Source
Completed
Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2)
NCT05281523· Phase 3· GlaxoSmithKline· Source
Completed
An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)
NCT05243680· Phase 3· GlaxoSmithKline· Source
Completed
A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype
NCT04718103· Phase 3· GlaxoSmithKline· Source
Completed
A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype
NCT04718389· Phase 3· GlaxoSmithKline· Source
Completed
An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments
NCT03828292· Phase 1· GlaxoSmithKline· Source
Completed
Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy
NCT01649765· Phase 2· GlaxoSmithKline· Source

Site data: ClinicalTrials.govUpdated 13 Nov 2026

Report an error